[go: up one dir, main page]

CY1110462T1 - Θεραπεια της ηπατικης ινωσης με αντισωματα εναντιον της ενσωματινης (ιντεγκρινης) αλφα v βητα 6 - Google Patents

Θεραπεια της ηπατικης ινωσης με αντισωματα εναντιον της ενσωματινης (ιντεγκρινης) αλφα v βητα 6

Info

Publication number
CY1110462T1
CY1110462T1 CY20091100011T CY091100011T CY1110462T1 CY 1110462 T1 CY1110462 T1 CY 1110462T1 CY 20091100011 T CY20091100011 T CY 20091100011T CY 091100011 T CY091100011 T CY 091100011T CY 1110462 T1 CY1110462 T1 CY 1110462T1
Authority
CY
Cyprus
Prior art keywords
treatment
fibos
integrin
beta
alpha
Prior art date
Application number
CY20091100011T
Other languages
English (en)
Inventor
Xiaozhu Huang
Dean Sheppard
Robert Pytela
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of CY1110462T1 publication Critical patent/CY1110462T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση παρέχει τη χρήση ενός αντισώματος που προσδένεται ειδικά στην ανβ6 και μπλοκάρει τη πρόσδεση ενός συνδεόμενου μορίου στην αvβ6, για τη κατασκευή ενός φαρμάκου για τη θεραπεία της ηπατικής ίνωσης σε ένα ασθενή.
CY20091100011T 1997-08-08 2009-01-08 Θεραπεια της ηπατικης ινωσης με αντισωματα εναντιον της ενσωματινης (ιντεγκρινης) αλφα v βητα 6 CY1110462T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5506097P 1997-08-08 1997-08-08
EP04022921A EP1504764B1 (en) 1997-08-08 1998-08-07 Treatment of liver fibrosis with antibodies against alpha V beta 6 integrin

Publications (1)

Publication Number Publication Date
CY1110462T1 true CY1110462T1 (el) 2015-04-29

Family

ID=21995323

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091100011T CY1110462T1 (el) 1997-08-08 2009-01-08 Θεραπεια της ηπατικης ινωσης με αντισωματα εναντιον της ενσωματινης (ιντεγκρινης) αλφα v βητα 6
CY20111100822T CY1111792T1 (el) 1997-08-08 2011-08-26 Θεραπεια της ινωσης της ουροδοχου κυστης με αντισωματα εναντιον της ενσωματινης (ιντεγκρινης) αλφα v βητα 6

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20111100822T CY1111792T1 (el) 1997-08-08 2011-08-26 Θεραπεια της ινωσης της ουροδοχου κυστης με αντισωματα εναντιον της ενσωματινης (ιντεγκρινης) αλφα v βητα 6

Country Status (23)

Country Link
US (5) US20020004482A1 (el)
EP (3) EP1504764B1 (el)
JP (2) JP2001513333A (el)
KR (1) KR100586202B1 (el)
CN (1) CN1267224A (el)
AT (3) ATE410179T1 (el)
AU (1) AU739283B2 (el)
BR (1) BR9814040A (el)
CA (1) CA2297736A1 (el)
CY (2) CY1110462T1 (el)
CZ (1) CZ299768B6 (el)
DE (2) DE69840113D1 (el)
DK (2) DK1930022T3 (el)
EE (1) EE04752B1 (el)
ES (3) ES2364703T3 (el)
HU (1) HU228900B1 (el)
IL (2) IL134288A0 (el)
NZ (2) NZ515955A (el)
PL (2) PL201716B1 (el)
PT (3) PT1504764E (el)
RU (1) RU2221589C2 (el)
TR (2) TR200202323T2 (el)
WO (1) WO1999007405A1 (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
EP1504764B1 (en) * 1997-08-08 2008-10-08 The Regents Of The University Of California Treatment of liver fibrosis with antibodies against alpha V beta 6 integrin
GEP20063844B (en) * 1999-04-22 2006-06-12 Biogen Idec Inc Using antagonist of integrin alpha-4 subunit for treatment of fibrosis
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
AU2002257162A1 (en) * 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
CA2478833C (en) 2002-03-13 2015-11-10 Biogen, Inc. Anti-.alpha.v.beta.6 antibodies
US20040048312A1 (en) * 2002-04-12 2004-03-11 Ronghao Li Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
EP1734996B1 (en) * 2004-04-02 2013-05-22 The Regents of The University of California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
EP2046374A4 (en) 2006-07-10 2010-05-05 Biogen Idec Inc COMPOSITIONS AND METHODS FOR GROWTH INHIBITION OF SMAD4-DEFICIENT TUMORS
CN103524619B (zh) * 2006-08-03 2016-10-05 阿斯利康(瑞典)有限公司 针对αVβ6的抗体及其应用
EP2087008A1 (en) * 2006-10-19 2009-08-12 The Regents of the University of California TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN alphaVbeta6
EP2537529B1 (en) * 2007-08-02 2018-10-17 Gilead Biologics, Inc. Loxl2 inhibitory antibodies and uses thereof
KR101046317B1 (ko) * 2008-07-04 2011-07-05 이종대 조력발전 방법 및 그 장치
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US10087252B2 (en) 2009-07-24 2018-10-02 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with αvβ5 integrin
KR20120054077A (ko) * 2009-08-21 2012-05-29 길리아드 바이오로직스, 인크. 폐 섬유증 장애의 치료를 위한 방법 및 조성물
JP2013502226A (ja) 2009-08-21 2013-01-24 ギリアド バイオロジクス，インク． リシル酸化酵素及びｌｏｘｌ２由来の触媒ドメイン
CA2789022A1 (en) * 2010-02-04 2011-08-11 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
EP2814509B1 (en) 2012-02-17 2018-05-16 Seattle Genetics, Inc. Antibodies to integrin v 6 and use of same to treat cancer
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
EP2784511A1 (en) 2013-03-27 2014-10-01 Universität Zürich Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma
JP6104312B2 (ja) * 2014-06-19 2017-03-29 日東電工株式会社 組織再生促進剤
HK1254295A1 (zh) * 2015-11-23 2019-07-19 默克专利股份有限公司 用於治疗纤维化和/或纤维化病症的抗-αＶ整合素抗体
KR20200044066A (ko) 2017-08-22 2020-04-28 바이오젠 엠에이 인코포레이티드 항-알파(v)베타(6) 항체를 함유하는 약제학적 조성물 및 투약 요법
CA3159414A1 (en) 2019-12-05 2021-06-10 Seagen Inc. Anti-av.beta.6 antibodies and antibody-drug conjugates
EP4520329A3 (en) * 2020-05-07 2025-05-14 Pliant Therapeutics, Inc. Treatment of respiratory diseases with amino acid compounds
CN120960406A (zh) * 2024-05-16 2025-11-18 浙江大学 靶向整合素αVβ6的CAR-免疫细胞在预防和/或治疗纤维化疾病中的应用
WO2026012032A1 (en) * 2024-07-10 2026-01-15 Wuxi Biologics (Shanghai) Co., Ltd. Antibodies against integrin and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
FI912858A7 (fi) 1988-12-20 1991-06-13 La Jolla Cancer Res Foundation Haavojen parantamisessa aktiivisia polypeptidipolymeerikonjugaatteja
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
DE69531187T2 (de) * 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
EP1504764B1 (en) * 1997-08-08 2008-10-08 The Regents Of The University Of California Treatment of liver fibrosis with antibodies against alpha V beta 6 integrin

Also Published As

Publication number Publication date
DE69840113D1 (de) 2008-11-20
IL134288A0 (en) 2001-04-30
US6316601B1 (en) 2001-11-13
ES2364703T3 (es) 2011-09-12
AU8774398A (en) 1999-03-01
RU2221589C2 (ru) 2004-01-20
US20010056076A1 (en) 2001-12-27
ATE511850T1 (de) 2011-06-15
ES2311131T3 (es) 2009-02-01
HUP0003547A2 (hu) 2001-02-28
PT1930022E (pt) 2011-08-01
US7544358B2 (en) 2009-06-09
KR20010022740A (ko) 2001-03-26
TR200202323T2 (tr) 2002-12-23
BR9814040A (pt) 2000-10-03
JP2001513333A (ja) 2001-09-04
CZ299768B6 (cs) 2008-11-19
PL341029A1 (en) 2001-03-26
HU228900B1 (en) 2013-06-28
US20040208878A1 (en) 2004-10-21
EP1504764B1 (en) 2008-10-08
PT1504764E (pt) 2009-01-14
US6692741B2 (en) 2004-02-17
KR100586202B1 (ko) 2006-06-07
EP1504764A1 (en) 2005-02-09
JP2009001587A (ja) 2009-01-08
EP1930022B1 (en) 2011-06-08
EE04752B1 (et) 2006-12-15
NZ502546A (en) 2002-02-01
EP0996460A4 (en) 2001-03-07
EP0996460B1 (en) 2005-01-12
EE200000068A (et) 2000-10-16
PT996460E (pt) 2005-04-29
DE69828614T2 (de) 2006-02-09
PL199014B1 (pl) 2008-08-29
NZ515955A (en) 2003-04-29
HUP0003547A3 (en) 2002-05-28
EP0996460A1 (en) 2000-05-03
US7150871B2 (en) 2006-12-19
ATE410179T1 (de) 2008-10-15
ATE286742T1 (de) 2005-01-15
WO1999007405A1 (en) 1999-02-18
CA2297736A1 (en) 1999-02-18
US20070148173A1 (en) 2007-06-28
CY1111792T1 (el) 2015-10-07
US20020004482A1 (en) 2002-01-10
IL134288A (en) 2008-07-08
ES2235350T3 (es) 2005-07-01
EP1930022A1 (en) 2008-06-11
AU739283B2 (en) 2001-10-11
TR200000374T2 (tr) 2000-09-21
CN1267224A (zh) 2000-09-20
CZ2000413A3 (cs) 2000-11-15
PL201716B1 (pl) 2009-05-29
DK1930022T3 (da) 2011-07-25
DK1504764T3 (da) 2008-11-17
DE69828614D1 (de) 2005-02-17

Similar Documents

Publication Publication Date Title
CY1110462T1 (el) Θεραπεια της ηπατικης ινωσης με αντισωματα εναντιον της ενσωματινης (ιντεγκρινης) αλφα v βητα 6
CY1106156T1 (el) Νεα χρηση βουδεσονιδης και φορμοτepολης
CY2010011I1 (el) Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
FI956019A7 (fi) Eristettyjä peptidejä, jotka muodostavat komplekseja MHC-molekyyli HLA -C-klooni-10:n kanssa, ja niiden käyttö
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
MX9700082A (es) Composicion que consiste de morfina, polipirrolidona y oxido de polialquileno.
CY1106992T1 (el) Καχαλαλιδη f και συναφεις ενωσεις
CY1108007T1 (el) Φαρμακευτικες συνθεσεις βοτουλινικης τοξινης
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
CY1108179T1 (el) Τροποποιημενος παραγοντας viii
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
PT820323E (pt) Inalador doseador para salmeterol
CY2010018I2 (el) Ενωσεις τυπου αμινοκυκλοεξυλο αιθερια και η χρηση των
ATE389721T1 (de) Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
DK1036058T3 (da) Adamantanderivater
EE200000378A (et) Adamantaani derivaadid
FR2715290B1 (fr) Agrafe chirurgicale à ligaments.
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
DK1104425T3 (da) Hidtil ukendte thiazolopyrimidinforbindelser
BR9811094A (pt) Agente terapêutico para tumores linfáticos
DE69819338D1 (de) Lipid haltige zusammenstellungen und deren verwendungen
CY1105211T1 (el) Φαρμακευτικοι συνδυασμοι που πepιλαμβανουν εναν ανταγωνιστη του υποδοχεα p2τ και μελαγατρανη